100 related articles for article (PubMed ID: 8535199)
1. Combination chemotherapy (RCM protocol: response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia.
Uozumi K; Hanada S; Ohno N; Ishitsuka K; Shimotakahara S; Otsuka M; Chyuman Y; Nakahara K; Takeshita T; Kuwazuru Y
Leuk Lymphoma; 1995 Jul; 18(3-4):317-23. PubMed ID: 8535199
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL).
Uozumi K; Nakahara K; Takatsuka Y; Ohno N; Makino T; Utsunomiya A; Hanada S; Arima T
Leuk Lymphoma; 1998 Apr; 29(3-4):407-14. PubMed ID: 9684938
[TBL] [Abstract][Full Text] [Related]
3. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma.
Matsushita K; Matsumoto T; Ohtsubo H; Fujiwara H; Imamura N; Hidaka S; Kukita T; Tei C; Matsumoto M; Arima N
Leuk Lymphoma; 1999 Dec; 36(1-2):67-75. PubMed ID: 10613451
[TBL] [Abstract][Full Text] [Related]
4. [ATL (adult T-cell leukemia/lymphoma)].
Ichimaru M; Tsukazaki K; Ikeda S
Rinsho Ketsueki; 1989 Aug; 30(8):1208-11. PubMed ID: 2601035
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.
Hermine O; Allard I; Lévy V; Arnulf B; Gessain A; Bazarbachi A;
Hematol J; 2002; 3(6):276-82. PubMed ID: 12522449
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma.
Tsukasaki K; Ikeda S; Murata K; Maeda T; Atogami S; Sohda H; Momita S; Jubashi T; Yamada Y; Mine M
Leuk Res; 1993 Feb; 17(2):157-66. PubMed ID: 8429692
[TBL] [Abstract][Full Text] [Related]
7. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.
Katsuya H; Yamanaka T; Ishitsuka K; Utsunomiya A; Sasaki H; Hanada S; Eto T; Moriuchi Y; Saburi Y; Miyahara M; Sueoka E; Uike N; Yoshida S; Yamashita K; Tsukasaki K; Suzushima H; Ohno Y; Matsuoka H; Jo T; Suzumiya J; Tamura K
J Clin Oncol; 2012 May; 30(14):1635-40. PubMed ID: 22473153
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
Bazarbachi A; Plumelle Y; Carlos Ramos J; Tortevoye P; Otrock Z; Taylor G; Gessain A; Harrington W; Panelatti G; Hermine O
J Clin Oncol; 2010 Sep; 28(27):4177-83. PubMed ID: 20585095
[TBL] [Abstract][Full Text] [Related]
9. Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
Guery R; Suarez F; Lanternier F; Bougnoux ME; Lecuyer H; Avettand-Fenoel V; Sibon D; Frenzel L; Raphalen JH; Helias P; Renaudier P; Santa F; Lecuit M; Lortholary O; Hermine O; Aguilar C; Marçais A
Ann Hematol; 2021 Nov; 100(11):2813-2824. PubMed ID: 34387741
[TBL] [Abstract][Full Text] [Related]
10. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Tominaga S; Tsugane S; Minato K
J Clin Oncol; 1988 Jul; 6(7):1088-97. PubMed ID: 2899140
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
12. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.
White JD; Wharfe G; Stewart DM; Maher VE; Eicher D; Herring B; Derby M; Jackson-Booth PG; Marshall M; Lucy D; Jain A; Cranston B; Hanchard B; Lee CC; Top LE; Fleisher TA; Nelson DL; Waldmann TA
Leuk Lymphoma; 2001 Jan; 40(3-4):287-94. PubMed ID: 11426550
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
[TBL] [Abstract][Full Text] [Related]
14. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
Jabbour E; Koscielny S; Sebban C; Peslin N; Patte C; Gargi T; Biron P; Fermé C; Bourhis JH; Vantelon JM; Arnaud P; Ribrag V
Leukemia; 2006 May; 20(5):814-9. PubMed ID: 16511514
[TBL] [Abstract][Full Text] [Related]
15. Treatment for adult T-cell leukemia.
Hanada S; Utsunomiya A; Suzuki S; Uozumi K; Makino T; Arima T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S47-50. PubMed ID: 9272134
[TBL] [Abstract][Full Text] [Related]
16. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Ishida T; Fujiwara H; Nosaka K; Taira N; Abe Y; Imaizumi Y; Moriuchi Y; Jo T; Ishizawa K; Tobinai K; Tsukasaki K; Ito S; Yoshimitsu M; Otsuka M; Ogura M; Midorikawa S; Ruiz W; Ohtsu T
J Clin Oncol; 2016 Dec; 34(34):4086-4093. PubMed ID: 27621400
[TBL] [Abstract][Full Text] [Related]
18. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
Toriyama E; Imaizumi Y; Taniguchi H; Taguchi J; Nakashima J; Itonaga H; Sato S; Ando K; Sawayama Y; Hata T; Fukushima T; Miyazaki Y
Int J Hematol; 2018 Aug; 108(2):167-175. PubMed ID: 29651666
[TBL] [Abstract][Full Text] [Related]
19. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
